News | April 09, 2015

Intra-aortic Balloon Pumps Cost-Effective First Treatment for High-Risk PCI Patients

New study finds percutaneous ventricular assist devices viable as second option for refractory patients

intraaortic balloon pumps, IABP, ventricular assist devices, VAD, cost effective

April 9, 2015 — Maquet Cardiovascular USA announced publication of a manuscript comparing the clinical and economic impact of percutaneous ventricular assist devices (pVAD) with intra-aortic balloon pumps (IABP) for high-risk patients undergoing percutaneous coronary intervention (PCI). The paper, titled "Clinical and Economic Effectiveness of Percutaneous Ventricular Assist Devices for High-Risk Patients Undergoing Percutaneous Coronary Intervention," appears in the March 2015 volume of the Journal of Invasive Cardiology.

The study, led by Atman P. Shah, M.D., associate professor of medicine, director, coronary care unit and co-director, cardiac catheterization laboratory at The University of Chicago, conducted a review of all comparative randomized control trials of the pVADS (Impella and TandemHeart) versus IABP for patients undergoing high-risk PCI. A retrospective analysis of the 2010 and 2011 Medicare MEDPAR data files was also performed to compare procedural costs and hospital length of stay (LOS). Readmission rates between the devices were also studied.

From a clinical standpoint, the study demonstrated no conclusive clinical benefit in trial patients treated with pVADs compared with IABP—despite the additional costs of pVADs. pVADs were not shown to be associated with improved clinical outcomes, reduced hospital length of stay or reduced readmission rates. Economically, first-line management of high-risk PCI and cardiogenic shock patients with IABP was shown to be more cost-effective than routine use of pVADS. Use of IABP as initial therapy in high-risk PCI and cardiogenic shock patients may result in savings of up to $2.5 billion annually of incremental costs to the hospital system.

"The cath lab has a long tradition of implementing therapies to take care of patients quickly and effectively," said Shah. "Using IABP as a first-line strategy for cardiogenic shock and high-risk PCI patients with an escalating approach toward pVADs for refractory patients makes clinical sense in that IABP is easy and quick to deploy in addition to being cost effective."

For more information: www.invasivecardiology.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init